DA
AUPH icon

Duality Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Duality Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,871
Closed -$109K – 533
2022
Q2 		$109K Buy
+10,871
New +$122K 0.01% 569

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Duality Advisers's AUPH Position: Q3 2022 in Review

Duality Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 10,871 shares — an estimated $109K sold.

Duality Advisers first reported a position in AUPH in Q2 2022 and held it in 1 quarter. The position peaked at $109K in Q2 2022. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

  • Duality Advisers reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Duality Advisers sold 10,871 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $109K.
  • Duality Advisers first reported a position in Aurinia Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Duality Advisers's Aurinia Pharmaceuticals position peaked at $109K in Q2 2022.
  • 189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on Duality Advisers's 13F filing for Q3 2022, filed 3 Nov 2022.